Physicians’ Knowledge and Awareness about Biosimilars in Saudi Arabia: What is Imperative to Know ??

Almalki, Ziyad S.; Iqbal, Muhammad Shahid; Alossaimi, Manal A.; Lasaf, Alwaleed Mohammed; Almawash, Bandar Abdullah; Aldossary, Fayez Hamoud; Marghalani, Aliyah Mohammed; Alsubaihi, Yazeed Abdulaziz

doi:10.5530/jyp.2020.12.76

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are rational as biosimilar formulations are a relatively new therapy approach whereby numerous healthcare professionals are not thoroughly familiar with. [19][20][21][22][23] Our study results are in contrast with Iga Pawłowska et al and Joan O'Callaghan et al who reported that the majority of the pharmacists in their studies expressed greater familiarity with biosimilar medications and their uses. 8,24 Moreover, the findings from many other similar studies from different parts of the world like New Zealand, the USA, Ireland, and the UK suggest that the majority of the healthcare professionals, especially pharmacists had adequate knowledge about biosimilar medications and their benefits, but still there are several knowledge and attitude gaps regarding biosimilar medications.…”

Section: Discussioncontrasting

confidence: 97%

Knowledge and Attitude of Pharmacists about Biosimilar Medications in Saudi Arabia

Alahmari

Almalki

Iqbal

et al. 2021

IJPI

Self Cite

View full text Add to dashboard Cite

Objectives: This study determined knowledge and attitude of pharmacists about biosimilar mdications in Saudi Arabia. Methods: Pharmacists from different areas and regions were approached to participate in this cross-sectional study. Data were collected by a pre-validated and selfadministered research tool using a convenience sampling technique. Analyses and interpretation of the data were done using descriptive and inferential statistics with Statistical Package for Social Sciences (SPSS) version 24.0. Results: A total of 319 pharmacists from different specialties participated in the study. A total of 111 pharmacists were males, and 208 were females. All of the pharmacists had varied expertise. Around 41.4% of the studied pharmacists were practicing in the community, 34.5% in hospitals and 24.1% were in other areas. Conclusion: This study reported the current level of pharmacists' knowledge and attitude about biosimilar medications in Saudi Arabia. Statistically, a significant association was observed between male and female pharmacists regarding the introduction of biosimilar medications in the Saudi Arabian healthcare setup.

show abstract

Section: Discussioncontrasting

confidence: 97%

Knowledge and Attitude of Pharmacists about Biosimilar Medications in Saudi Arabia

Alahmari

Almalki

Iqbal

et al. 2021

IJPI

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study has assessed the pharmacists' knowledge level and views about biosimilar medicines in Jordan and to explore the predictors which could influence their knowledge. Few surveys have been conducted to assess pharmacists' knowledge and attitude toward biosimilars in Middle-East countries [ 26 , 27 ], and up to our knowledge this is the first questionnaire survey that has been conducted in Jordan.…”

Section: Discussionmentioning

confidence: 99%

Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan

Oqal

Hijazi

Alqudah

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

Aims. Pharmacists in all clinical settings are recognized drug experts and integral educators of biosimilar medicines. Therefore, the objective of this study was to assess pharmacists’ knowledge, predictors of knowledge, and views toward biosimilar medicines in Jordan. Methods. A cross-sectional study was conducted in Jordan during October–December 2020. An Internet-based self-administrated questionnaire on knowledge and views was distributed using social media groups to the pharmacists among different areas in Jordan. A descriptive and univariate analysis was performed. Binary logistic regression was conducted to determine the predictors of knowledge including all variables with p < 0.20 on univariate analysis. Results. A total 536 responses were received, 502 of which were completed (93.7% response rate). A total of 52.6% of the pharmacists were knowledgeable about biosimilar medicines and the mean of knowledge level was 6.47 ± 1.62 (range 2–10). Multivariate analysis identified that respondents who had heard about biosimilars before (OR = 1.942, 95% CI = 1.231–3.063, p < 0.05 ) was more likely to be knowledgeable. Respondents who had not taken the course or the postgraduating training course about biosimilars that were less likely to be knowledgeable (OR = 0.548, 95% CI = 0.357–0.839, p < 0.05 ). A positive response was noted in pharmacist’s view regarding the implementation of biosimilar medicines in healthcare setting, biosimilar medicine prescription related to decreased costs, self-study about biosimilar medicine, and incorporating biosimilar education program at the pharmacy school curriculum universities level. Conclusions. Pharmacists’ views and knowledge vary regarding the particularities and key issues on biosimilar medicines in Jordan. Incorporating biosimilar course in pharmacy school curriculum could improve their acceptance for future pharmacy jobs.

show abstract

“…To date, there is a lack of published data about the awareness and the knowledge of physicians about biosimilars [10]. So, the aim of this study was to investigate physicians' opinions on the required information about biosimilars and the need for biosimilars related education.…”

Section: Introductionmentioning

confidence: 99%

Physicians' Opinions on the Required Information about Biosimilars and the Need for Biosimilars Related Education

Ahmed

2021

JPRI

View full text Add to dashboard Cite

Aim: The aim of this study was to investigate physicians' opinions on the required information about biosimilars and the need for biosimilars related education. Methodology: The study included a survey that was prepared using a survey from a previous study and after face validation and content validation, it was prepared as an online form using the SurveyMonkey platform. Results: The majority of physicians stated that the most important information about biosimilars are studies that provide clinical immunogenicity data for the biosimilar and reference product (93.33%) in addition to studies that directly compare clinical efficacy and safety between reference products and biosimilars (88.89%). The majority of physicians stated that tracking safety events with biosimilars (94.45%) and access to information on studies comparing biosimilars with reference biologics (91.11%) are important issues related to biosimilars in professional environments. Conclusion: The present study highlights the needs of physicians for biosimilar education. More efforts are needed to increase the awareness regarding biosimilars by different formats in order to integrate biosimilars into clinical practice and to counsel patients about biosimilars.

show abstract

Physicians’ Knowledge and Awareness about Biosimilars in Saudi Arabia: What is Imperative to Know ??

Cited by 5 publications

References 18 publications

Knowledge and Attitude of Pharmacists about Biosimilar Medications in Saudi Arabia

Knowledge and Attitude of Pharmacists about Biosimilar Medications in Saudi Arabia

Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan

Physicians' Opinions on the Required Information about Biosimilars and the Need for Biosimilars Related Education

Contact Info

Product

Resources

About